SE468881B - Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar - Google Patents

Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Info

Publication number
SE468881B
SE468881B SE9100059A SE9100059A SE468881B SE 468881 B SE468881 B SE 468881B SE 9100059 A SE9100059 A SE 9100059A SE 9100059 A SE9100059 A SE 9100059A SE 468881 B SE468881 B SE 468881B
Authority
SE
Sweden
Prior art keywords
endotoxin
preparation
immobilized
formula
agmatine
Prior art date
Application number
SE9100059A
Other languages
English (en)
Swedish (sv)
Other versions
SE9100059D0 (sv
SE9100059L (sv
Inventor
S Lindgren
C Grimfors
G Sandberg
R Wahlen
B Westberg
E Lampen
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9100059A priority Critical patent/SE468881B/sv
Publication of SE9100059D0 publication Critical patent/SE9100059D0/xx
Priority to DK96104316T priority patent/DK0719550T3/da
Priority to AU91528/91A priority patent/AU9152891A/en
Priority to DK92903332.2T priority patent/DK0566644T3/da
Priority to AT96104316T priority patent/ATE204753T1/de
Priority to EP92903332A priority patent/EP0566644B1/en
Priority to JP50360692A priority patent/JP3200604B2/ja
Priority to AT92903332T priority patent/ATE157866T1/de
Priority to EP96104316A priority patent/EP0719550B1/en
Priority to PCT/SE1991/000893 priority patent/WO1992011847A1/en
Priority to ES96104316T priority patent/ES2163543T3/es
Priority to DE69223426T priority patent/DE69223426T2/de
Priority to DE69132710T priority patent/DE69132710T2/de
Priority to ES92903332T priority patent/ES2109338T3/es
Priority to EP92850001A priority patent/EP0494848B1/en
Priority to PT95118986T priority patent/PT715849E/pt
Priority to EP95118986A priority patent/EP0715849B1/en
Publication of SE9100059L publication Critical patent/SE9100059L/
Publication of SE468881B publication Critical patent/SE468881B/sv
Priority to GR970403223T priority patent/GR3025573T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61L2103/05—

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SE9100059A 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar SE468881B (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
ES92903332T ES2109338T3 (es) 1991-01-09 1991-12-20 Metodo para separar endotoxinas.
EP96104316A EP0719550B1 (en) 1991-01-09 1991-12-20 A method of inhibiting endotoxin induced effects
ES96104316T ES2163543T3 (es) 1991-01-09 1991-12-20 Metodo para inhibir los efectos inducidos por endotoxinas.
DK92903332.2T DK0566644T3 (da) 1991-01-09 1991-12-20 Fremgangsmåde til fjernelse af endotoksiner
AT96104316T ATE204753T1 (de) 1991-01-09 1991-12-20 Verfahren zur reduzierung von endotoxin induzierten effekten
EP92903332A EP0566644B1 (en) 1991-01-09 1991-12-20 Method of removing endotoxins
JP50360692A JP3200604B2 (ja) 1991-01-09 1991-12-20 菌体内毒素誘発作用抑制方法
AT92903332T ATE157866T1 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen
DK96104316T DK0719550T3 (da) 1991-01-09 1991-12-20 Fremgangsmåde til inhibering af endotoxinfremkaldte virkninger
PCT/SE1991/000893 WO1992011847A1 (en) 1991-01-09 1991-12-20 A method of inhibiting endotoxin induced effects
AU91528/91A AU9152891A (en) 1991-01-09 1991-12-20 A method of inhibiting endotoxin induced effects
DE69223426T DE69223426T2 (de) 1991-01-09 1991-12-20 Verfahren zur entfernung von endotoxinen
DE69132710T DE69132710T2 (de) 1991-01-09 1991-12-20 Verfahren zur Reduzierung von Endotoxin induzierten Effekten
EP95118986A EP0715849B1 (en) 1991-01-09 1992-01-03 A method of inhibiting endotoxin induced effects
EP92850001A EP0494848B1 (en) 1991-01-09 1992-01-03 Method of removing endotoxins
PT95118986T PT715849E (pt) 1991-01-09 1992-01-03 Metodo de reducao dos efeitos induzidos pela endotoxina
GR970403223T GR3025573T3 (en) 1991-01-09 1997-12-02 Method of removing endotoxins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Publications (3)

Publication Number Publication Date
SE9100059D0 SE9100059D0 (sv) 1991-01-09
SE9100059L SE9100059L (sv) 1992-07-10
SE468881B true SE468881B (sv) 1993-04-05

Family

ID=20381566

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9100059A SE468881B (sv) 1991-01-09 1991-01-09 Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar

Country Status (11)

Country Link
EP (4) EP0719550B1 (enExample)
JP (1) JP3200604B2 (enExample)
AT (2) ATE204753T1 (enExample)
AU (1) AU9152891A (enExample)
DE (2) DE69132710T2 (enExample)
DK (2) DK0566644T3 (enExample)
ES (2) ES2109338T3 (enExample)
GR (1) GR3025573T3 (enExample)
PT (1) PT715849E (enExample)
SE (1) SE468881B (enExample)
WO (1) WO1992011847A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
ES2196053T3 (es) * 1994-01-11 2003-12-16 Stichting Zofia Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
DE69827149T2 (de) * 1997-08-15 2006-03-09 Fairbanks, Carolyn Ann, Rochester Agmatin für die behandlung neuropathischer schmerzen
US6774102B1 (en) 1999-09-29 2004-08-10 Gambro Dialysatoren Gmbh & Co. Kg Extracorporeal endotoxin removal method
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
SE526038C2 (sv) * 2002-07-08 2005-06-21 Gambro Lundia Ab Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
CA2655873C (en) 2006-07-14 2017-10-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA939265A (en) * 1967-11-18 1974-01-01 Yoshitaka Ikezuki Injectable compositions for alleviating the pain incurred from administrations of injections
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
JPH01238534A (ja) * 1988-03-17 1989-09-22 Mitsui Toatsu Chem Inc エンドトキシンの除去方法
US5019558A (en) * 1988-05-09 1991-05-28 Georges Cehovic Method for treating memory disturbances using arginine aspartate
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation

Also Published As

Publication number Publication date
EP0719550A3 (enExample) 1996-07-24
WO1992011847A1 (en) 1992-07-23
DK0719550T3 (da) 2001-12-10
SE9100059D0 (sv) 1991-01-09
GR3025573T3 (en) 1998-03-31
DK0566644T3 (da) 1998-04-27
AU9152891A (en) 1992-08-17
ATE204753T1 (de) 2001-09-15
EP0719550B1 (en) 2001-08-29
EP0715849B1 (en) 2001-07-25
DE69223426T2 (de) 1998-03-12
DE69132710D1 (de) 2001-10-04
PT715849E (pt) 2002-01-30
ES2163543T3 (es) 2002-02-01
EP0715849A1 (en) 1996-06-12
EP0494848A1 (en) 1992-07-15
EP0566644B1 (en) 1997-09-10
DE69132710T2 (de) 2002-04-18
EP0494848B1 (en) 1997-03-26
EP0719550A2 (en) 1996-07-03
ATE157866T1 (de) 1997-09-15
JP3200604B2 (ja) 2001-08-20
EP0566644A1 (en) 1993-10-27
ES2109338T3 (es) 1998-01-16
SE9100059L (sv) 1992-07-10
JPH06504058A (ja) 1994-05-12
DE69223426D1 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
SE468881B (sv) Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
Riegel et al. Plasma levels of main granulocyte components during cardiopulmonary bypass
US5652211A (en) Peptides for neutralizing the toxicity of Lipid A
CA2212125A1 (en) Process for producing a protein
JPH06211900A (ja) 水性液体から腫瘍壊死因子または／およびリポ多糖を定量的、選択的に除去するかまたは／および調製的に製取する方法、液体から腫瘍壊死因子および／またはリポ多糖を体外除去する装置、装置ユニットおよび吸着材料
Nishioka et al. Tuftsin: a hormone-like tetrapeptide with antimicrobial and antitumor activities
EP1226829B1 (de) Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
EP0593585B1 (en) Peptide which abrogates tnf and lps toxicity
JP2012102115A (ja) ナノ濾過工程を含むアルブミン精製方法、それを含有する治療用途のための溶液及び組成物
WO1994005696A1 (fr) Nouveau peptide et agent antithrombotique, anticoagulant pour la circulation extracorporelle, inhibiteur de fusion cellulaire, inhibiteur de metastases cancereuses, agent de protection de preparation plaquettaire pour la transfusion, et ensemble contenant une preparation plaquettaire pour la transfusion
JPS63165328A (ja) 組織タンパクｐｐ４含有医薬
Buoncristiani et al. Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes
JPWO2001024790A1 (ja) カルボニルストレス改善剤
NL8006706A (nl) Farmaceutische preparaten van therapeutische waarde voor het behandelen van acute longoedemen, sommige shocktoestanden en hyperfibrinolyse.
JP2025533238A (ja) 液体ダルババンシン組成物
EP4341393A1 (en) Process for isolating plasminogen from a blood plasma fraction
FI62103C (fi) Foerfarande foer framstaellning av heparin med hoeg specifik aktivitet
JP2003019198A (ja) 腹膜透析液
WO1995001371A1 (en) Novel peptide and antiplatelet aggregation containing the same
RU2175240C1 (ru) Средство для парентерального белкового питания и снятия токсемии
EP4633781A1 (en) Process of manufacturing a device and device for the treatment of fluids
JP2014159414A (ja) Ｓｔｘ２阻害４価ペプチドおよびこのＳｔｘ２阻害４価ペプチドを含む治療薬
Shimizu et al. Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs
SK280751B6 (sk) Spôsob prípravy krvného albumínu na terapeutické ú
JPH04300900A (ja) ペプチド複合体、及びそれを有効成分とする癌転移阻害剤

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 9100059-6

Format of ref document f/p: F

NUG Patent has lapsed